Immune System Key

Immune System Key Overview

Immune System Key (ISK) is engaged in the discovery and development of treatments for malignant cancers and autoimmune diseases, with a primary focus on treating patients with acute myeloid leukemia (AML), pancreatic cancer, and triple-negative breast cancer. Its assets are based on novel human-secreted peptides that were discovered by the company's founders. ISK's lead compound is Nerofe, which offers the potential to inhibit all three biological processes that support cancer progression. In phase-1 testing, researchers demonstrated induction of a strong anti-angiogenic effect and activation of anticancer immune response. In addition, in-vitro experiments indicate that Nerofe may have a strong inhibitory effect on cancer cell proliferation. Nerofe was granted orphan status by the FDA for the treatment of AML. The company has also developed a novel marker whose presence in a patient's biopsy can help predict the success of treatment with Nerofe.

Cumulative Funding Raised Over Time ($)

Latest News

Apr 9, 2019 · www.immunesk.com

http://www.immunesk.com/prof-marc-e-lippman-famous-breast-cancer-expert-kol-has-joined-isk-ltd/

Nov 21, 2018 · www.immunesk.com

http://www.immunesk.com/nerofe-has-received-a-new-us-patent-for-metastatic-cancer-treatment/

Feb 4, 2018 · www.immunesk.com

http://www.immunesk.com/pmwc-2018-conference-new-technology-presented/

Nov 21, 2017 · www.immunesk.com

http://www.immunesk.com/successful-completion-phase-nerofe-trial-solid-tumors/

Funding

Team Members

3

Employees: 1-10

Web & Social Links

Locations

Yossele Rosenblatt St 318, Jerusalem

Photos & Videos

1 item(s)

Immune System Key Internal

Recent Updates

No update log entries.

Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.

Admin Info